Skip to content
Medical Health Aged Care

Dr. Daniel Pascheles Rejoins Molekule Consulting as Strategic Advisor

Molekule Consulting, LLC 2 mins read

MIAMI, FL / ACCESSWIRE / October 30, 2023 / In a significant development that promises to shape the future of Molekule Consulting, we are thrilled to announce the return of Dr. Daniel Pascheles as a Strategic Advisor.

Molekule Consulting
Molekule Consulting
www.molekuleconsulting.com

Dr. Pascheles, with an illustrious career spanning over 30 years in the biopharmaceutical competitive and strategic intelligence sector, is poised to bring a wealth of knowledge and expertise to Molekule. His previous roles include leading Competitive Intelligence & Strategy functions at industry leaders Merck & Co./MSD and Aventis, in addition to serving as CEO of Molekule Consulting.

"Dr. Pascheles' return-to-Molekule marks a thrilling, new chapter in our shared story. His homecoming is not just a reunion, but a renewal of our mutual commitment to excellence and innovation. Welcome back, Dr. Pascheles!" expressed David Alderman, President & CEO at Molekule Consulting.

In his pivotal role as Strategic Advisor, Dr. Pascheles will employ his vast industry expertise and strategic prowess to shape and foster Molekule's trajectory of growth and value journey into the future.

"I am thrilled to be back!" remarked Dr. Pascheles. "It is with great excitement that I rejoin the dynamic and growing team at Molekule, and I eagerly anticipate contributing to the company's ongoing success."

For further details on this exciting development, please contact David Alderman at dalderman@molekuleconsulting.com; +1 305.504.3030.

About Molekule Consulting:

Molekule Consulting provides best-in-class strategic intelligence and is solely dedicated to the biopharma sector. We shape the path forward with our strategic intelligence, driving transformative changes across the biopharmaceutical landscape.

Our purpose is clear: to provide high-impact, actionable insights that catalyze growth and foster innovation for biopharmaceutical brands, franchises, and businesses. Our clientele encompasses industry titans, robust mid-sized companies, and ambitious newcomers within the global biopharmaceutical realm.

Interested in learning more about Molekule Consulting's biopharmaceutical-focused strategies and market intelligence? Dive deeper here: www.molekuleconsulting.com

Contact Information

David Alderman
President & CEO
dalderman@molekuleconsulting.com
+1 305.504.3030

SOURCE: Molekule Consulting

.


View source version on accesswire.com:
https://www.accesswire.com/797610/dr-daniel-pascheles-rejoins-molekule-consulting-as-strategic-advisor

More from this category

  • Medical Health Aged Care
  • 27/05/2024
  • 14:21
Dementia Australia

Community turns out in force to support people impacted by dementia

Thank you to Brisbane community members who turned up in force to the 2024 Memory Walk & Jog, showing their support for Australians living with dementia. More than 1,200 people walked, ran and jogged on Sunday 26 May raising an impressive total of $135,000! Dementia Australia Executive Director Services, Advocacy & Research Dr Kaele Stokes said it was a wonderful occasion and extended her gratitude to all who participated, raised funds, spread the word and donated. “There was an outstanding show of support from the Brisbane community who turned out in such large numbers for another year. So many people…

  • Contains:
  • Medical Health Aged Care
  • 27/05/2024
  • 13:09
UNSW Sydney

Ozempic found to reduce risk of kidney disease and death in people with diabetes

A popular diabetes medication has been found to prevent kidney failure and reduce deaths in people with type 2 diabetes and chronic kidney disease. Antidiabetic medication semaglutide, more widely known by brand names Ozempic and Wegovy, significantly reduces the risk of kidney failure, substantial loss of kidney function and death from kidney or cardiovascular causes, an international clinical trial led by UNSW Sydney researchers has shown. The trial involving more than 3500 participants with type 2 diabetes and chronic kidney disease from 28 countries – including Australia, the USA and China – found a small weekly dose of semaglutide reduced…

  • Medical Health Aged Care
  • 27/05/2024
  • 12:24
Dementia Australia

Community turns out in force to support people impacted by dementia

Thank you to Perth community members who turned up in force to the 2024 Memory Walk & Jog, showing their support for Australians living with dementia. More than 1,000 people walked, ran and jogged on Sunday 26 May raising an impressive total of $140,000! Dementia Australia Executive Director Services, Advocacy & Research Dr Kaele Stokes said it was a wonderful occasion and extended her gratitude to all who participated, raised funds, spread the word and donated. “There was an outstanding show of support from the Perth community who turned out in such large numbers for another year. So many people…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.